JPMorgan Upgrades Zymergen Inc (ZY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts ZY Hot Sheet
Rating Summary:
0 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 23 | New: 0
Join SI Premium – FREE
JPMorgan analyst Tycho Peterson upgraded Zymergen Inc (NASDAQ: ZY) from Underweight to Neutral.
The analyst comments "Monday morning, Ginkgo Bioworks (DNA) announced that it will acquire ZY in an all-stock transaction valued at ~$300M. The deal is expected to close by 1Q23. ZY also announced it will be reducing its workforce by ~80 employees and gave minimal product portfolio updates including pausing the Z-1 program with Sumitomo due to lack of demand. All in, in light of the deal we are moving from an Underweight rating to Neutral. We do not have a PT on ZY."
For an analyst ratings summary and ratings history on Zymergen Inc click here. For more ratings news on Zymergen Inc click here.
Shares of Zymergen Inc closed at $2.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) PT Raised to $184 at BMO Capital
- Harley-Davidson (HOG) PT Raised to $35 at BofA Securities
- SanDisk (SNDK) PT Lowered to $2,000 at BofA Securities
Create E-mail Alert Related Categories
Analyst Comments, UpgradesRelated Entities
JPMorgan, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
